| Why carry out this study? |
| KEYNOTE-048 showed that the programmed death receptor 1 inhibitor pembrolizumab improves survival in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). |
| We assessed whether pembrolizumab is cost-effective over cetuximab + platinum + 5-fluorouracil in Argentina, as monotherapy in patients with combined positive score (CPS) ≥1, and in combination with platinum + 5-fluorouracil in the total population. |
| What was learned from the study? |
| Pembrolizumab monotherapy and combination therapy cost AR $170,985 (2311 USD) and AR $858,306 (11599 USD) per QALY gained, respectively, making pembrolizumab a cost-effective option in Argentina. |
| The results support access to pembrolizumab for patients with R/M HNSCC in Argentina. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.